Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

EAU NMIBC Risk Stratification (2024)

The EAU Guidelines stratify Non-Muscle Invasive Bladder Cancer (NMIBC) into four risk groups (Low, Intermediate, High, Very High) to determine adjuvant treatment.

Evidence-based context for fast calculator use

Purpose:
EAU NMIBC Risk Stratification classifies bladder cancer into Low to Very High risk groups to guide BCG therapy and cystectomy decisions.
Population:
patients with non-muscle-invasive or urothelial cancer in the recurrence/progression setting described by the model
Factors:
T-Stage, Grade, Carcinoma In Situ?, Tumor Size, Multifocality, Recurrence Status, Age > 70?, Variant Histology?
Reference:
Sylvester RJ, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-488. (Adopted in EAU Guidelines 2024).
HomeEAU NMIBC Risk Stratification (2024)
Pin your most used calculators here by clicking the star in the dropdown.

EAU NMIBC Risk Stratification (2024)

Clinical Context & Background

The EAU Guidelines stratify Non-Muscle Invasive Bladder Cancer (NMIBC) into four risk groups (Low, Intermediate, High, Very High) to determine adjuvant treatment. This stratification guides the use of single instillation chemotherapy, maintenance BCG, or early radical cystectomy.
Primary Source EvidenceSylvester RJ, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-488. (Adopted in EAU Guidelines 2024).
Formula Logic
Algorithmic classification based on Stage, Grade, Size, Number, Age, and CIS.

Reference Data

Risk GroupTreatment Recommendation
LowSingle post-op chemo instillation
IntermediateChemo instillation or BCG (1 yr)
HighBCG maintenance (1-3 yr)
Very HighConsider Radical Cystectomy

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use EAU NMIBC Risk Stratification (2024) when eAU NMIBC Risk Stratification classifies bladder cancer into Low to Very High risk groups to guide BCG therapy and cystectomy decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through Very High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm stage, grade, CIS, tumor number and size, prior recurrence, BCG exposure, pathology review, and guideline risk group.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Historical EORTC, CUETO, and contemporary EAU groups use different populations and should not be interchanged.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with non-muscle-invasive or urothelial cancer in the recurrence/progression setting described by the model

How to apply this result

For a representative case, verify T-Stage, Grade, Carcinoma In Situ?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

EORTC NMIBC Risk Calculator — Bladder Cancer Recurrence & ProgressionCUETO Risk Score (BCG-Treated)

Frequently Asked Questions

When should EAU NMIBC Risk Stratification (2024) be used?

Use it for patients with non-muscle-invasive or urothelial cancer in the recurrence/progression setting described by the model when all required inputs and the intended clinical setting are confirmed.

Can EAU NMIBC Risk Stratification (2024) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.